This article outlines the protocol for a randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of high-dose intravenous zinc as an adjunctive therapy in critically ill patients with confirmed SARS-CoV-2 infection. Conducted at a single center in Australia, the study aims to enroll adult patients admitted to
